After Pasteurian microbiology then PCR, Dendris offers the diagnosis’ new standard allowing the simultaneous identification of a wide panel of pathogens with high sensitivity and specificity.
An innovative triple combination BIO – NANO – INFO revolutionizes molecular diagnostics. Through the identification of pathogens by their DNA, DendrisKITS enable automatic, reliable and rapid syndromic diagnosis on many types of samples.
Syndromic molecular biology
The syndromic approach aims to identify in a single analysis all the pathogens potentially responsible for a syndrome.
Backed by molecular biology, the identification of pathogens is done by their genotyping (DNA) instead of the phenotypic identification of microbiology.
Dendrimers
Functionalizing the substrate with phosphorus dendrimers considerably enhances the sensitivity of our chip. Dendris has filed a patent on the Dendrimers surface chemistry process.
Artificial intelligence
The machine-learning algorithm developed by Dendris delivers results from analyzed clinical samples automatically, reliably and fast.
The DendrisKIT DP is dedicated to the identification of 12 fungi involved in dermatophytosis.
CE-IVD mark
Learn more
The DendrisKIT OA allows the detection of 22 bacteria responsible for deep and osteoarticular infections, as well as the mecA resistance gene.
CE-IVD mark
The DendrisKIT IR panel makes it possible to identify in a single test the presence of 24 pathogens responsible for upper and lower respiratory infections.
In development
Learn more
The DendrisKIT MI is dedicated to the identification of targets involved in invasive pulmonary and blood mycoses.
Learn more
Develop easy-to-use in vitro molecular diagnostic kits for a syndromic approach to diseases or for the validation of biomarkers.
Our kits dedicated to hospitals and private laboratories favor an intuitive user interface. In a single test, a rapid and precise result accelerates the implementation of medical treatment. This solution contributes to:
– reduction of therapeutic expenses
– reduction in length of hospitalization
– improvement of clinical results and diagnoses
– the implementation of care protocols
We will have the pleasure of meeting you during the 2024 congresses on our stands:
We will be present at RICAI 2023 at the Palais des Congrès in Paris on December 18 and 19!
Come meet us on our stand 26a to discover (or rediscover!) our innovative BMS solution!
See you soon !
Dendris will be present at the 2023 edition of EBJIS in Basel, Switzerland!
Meet us at stand 20 to find out more about our BMS solution for osteoarticular infections!
Dendris was present during Medicen Day 2023 on September 26 in Paris.
Dendris was one of the 11 winners to pitch to investment funds during the Invest in Biomed day on July 6, 2023 in Marseille!
Dendris will be at the SFP/SFMM 2023 edition conference in Marrakech!
Come and discover our unique BIO-NANO-INFO solution! See you soon!
Dendris will be present at ECCMID in Copenhagen!
VISIT US AT THE EN-11 BOOTH!
We hope lots of you come !
Dendris will be present at BIOMED-J !
FIND US AT STAND #11!
Thursday 9 & Friday 10 March 2023 - Palais des Congrès de Paris
See you soon !
The multiplex DNA chip search for different pathogens was of particular interest to us. Indeed, in a single analysis, we can search for a panel of more than 20 pathogens compared to a few with traditional PCR methods.
We find common values of innovation and excellence and we keep our group at the cutting edge of technology.
Diagnosis and treatment are significantly accelerated, which benefits both our healthcare partners and our patients.
The latest developments from the Dendris company perfectly meet our needs…
We are satisfied with the partnership with the Dendris company.
Exchanges with the various stakeholders are fluid and constructive.
